Local biotech firm wins OK on cancer drug

Nov 6th, 2009 - Boston

Related content:

Gloucester Pharmaceuticals, a six-year-old Cambridge biotechnology start-up, has won approval from the Food and Drug Administration to market its first drug in the United States.

The drug, called Istodax, treats a rare skin cancer known as cutaneous T-cell lymphoma, or CTCL. Roughly 20,000 people in the United States have the cancer, which affects the immune system. The drug could be made available in January for some patients, Gloucester chief executive Alan Colowick said yesterday.

Read the whole story on Boston or try our Toolbar

blog comments powered by Disqus

Lawmakers fight raw-oyster ban under FDA rule
Nov 8th, 2009 - Washington Times
Gulf Coast lawmakers have a message for the administration: Keep your mitts off my raw oysters. Senators from Louisiana and Florida are seething over plans to sanitize...
A Warning on Web Sales of Cigarettes
Nov 7th, 2009 - New York Times
RICHMOND, Va. (AP) — The Food and Drug Administration said Friday that it had warned several companies to stop selling banned flavored cigarettes to consumers online.
FDA warns Web sites not to sell banned flavored cigarettes, thought to appeal to new smokers
Nov 6th, 2009 - Los Angeles Times
RICHMOND, Va. (AP) - The Food and Drug Administration said Friday that it has warned several companies to stop selling banned flavored cigarettes to U.S. consumers online.
FDA warns against erectile dysfunction supplement
Nov 6th, 2009 - Los Angeles Times
The Food and Drug Administration is warning consumers that Stiff Nights, a "dietary supplement" used to promote erections, contains an illegal drug and is potentially dangerous. Following a complaint...
BEFORE THE BELL-Sunesis shares rally after FDA move
Nov 5th, 2009 - Forbes
NEW YORK, Nov 5 (Reuters) - Shares of Sunesis Pharmaceuticals rose 45 percent to 55 cents in premarket trading on Thursday, after the company said one of its drugs had received orphan drug designation from the Food and Drug Administration.